However, clinical trials assessing the benefit of IFN-α and IFN-β therapy in the treatment of HAM/TSP have been less successful [46]; few patients showed any improvement and the overall clinical benefit was limited. The gene discussed is IFNB1; the disease is tropical spastic paraparesis.